Nuvo research is definitely one of the most undervalued stock in the Biotech Sector .
FDA approval for the "Best in Class topical medication" on March 4 ,2013 . Nuvo has already a fantastic Partnership with Big Player Covidien in place .
Nuvo will hit profitability this year with 2 product launches in 2Q 2013 .
Upcoming Milestones 2013 :
March 4, 2013 PDUFA date for Pennsaid 2%
Q2 2013 worldwide launch of Pliaglis by Galderma
.....
My Target is $0.30++ by mid 2013 !GLTA
Nuvo Research (NRI.TO)
Market Cap : $ 36 M
Cash: $ 12 M
Price 0.065 $
Presentation Jan 2013
http://www.nuvoresearch.com/investors/documen...ns/2013-...
-Specialty pharmaceutical company (TSX:NRI)
• U.S. based Pain Group
• Germany based Immunology Group
- Growing revenue with 3 approved pain products:
- Pennsaid®: topical NSAID for osteoarthritis, partnered with Covidien for
U.S., targeting $8B oral NSAID market
- Pliaglis®: analgesic peelable cream, targeting global cosmetic and
dermatology markets, partnered with Galderma, worldwide launch
commencing Q2 2013
- Synera®: analgesic patch for needle stick pain, targeting U.S. dialysis and
infusion centers
- Potential game changing immunology platform with positive Phase 2
results in allergic rhinitis
Nuvo Research Inc. is a publicly traded (TSX:NRI), Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition.
The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company’s product portfolio includes Pennsaid®, Pliaglis® and Synera®.
Pennsaid, a topical NSAID, is used to treat the signs and symptoms of OA of the knee(s). Pennsaid is sold in the United States by Mallinckrodt Inc., the pharmaceuticals business of Covidien, in Canada by Paladin Labs Inc. (TSX
LB) and in several European countries.
Pliaglis is a topical local anesthetic cream, which is FDA-approved to provide topical local analgesia for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global company dedicated to dermatology.
Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact skin. Nuvo currently markets Synera in the United States and its licensing partner, EuroCept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan®) in several European countries.
Through its subsidiary, Nuvo Research GmbH, based in Leipzig, Germany, the Company is also developing the compound WF10, for the treatment of immune related diseases
